The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion

被引:186
|
作者
Reffelmann, Thorsten [1 ]
Kloner, Robert A. [1 ]
机构
[1] Univ So Calif, Good Samaritan Hosp, Dept Cardiol, Div Cardiovasc Med,Keck Sch Med, Los Angeles, CA 90017 USA
关键词
no-reflow; ischemia; reperfusion; myocardial blood flow; myocardial infarction;
D O I
10.1007/s00395-006-0615-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both animal models of experimental myocardial infarction and clinical studies on reperfusion therapy for acute myocardial infarction have provided evidence of impaired tissue perfusion at the microvascular level after initiation of reperfusion despite adequate restoration of epicardial vessel patency. Characteristics of this "no-reflow" phenomenon found in basic science investigations, such as distinct perfusion defects, progressive decrease of resting myocardial flow with ongoing reperfusion and functional vascular alterations are paralleled by clinical observations demonstrating similar features during the course of reperfusion. In experimental animal investigations of coronary occlusion and reperfusion, this no-reflow phenomenon could be characterized as a fundamental mechanism of myocardial ischemia and reperfusion. Major determinants of the amount of no-reflow are the duration of occlusion, infarct size, but also the length of reperfusion, as rapid expansion of perfusion defects occurs during reperfusion. Moreover, no-reflow appears to persist over a period of at least four weeks, a period when major steps of infarct healing take place. The significant association of the degree of compromised tissue perfusion at four weeks and indices of infarct expansion, found in chronic animal models of reperfused myocardial infarction, might be the pathoanatomic correlate for the prognostic significance observed in the clinical setting.
引用
收藏
页码:359 / 372
页数:14
相关论文
共 50 条
  • [41] No-reflow phenomenon and prognosis in patients with acute myocardial infarction
    Ito, Hiroshi
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2006, 3 (09): : 499 - 506
  • [42] No-reflow after stroke reperfusion therapy: An emerging phenomenon to be explored
    Jia, Milan
    Jin, Feiyang
    Li, Sijie
    Ren, Changhong
    Ruchi, Mangal
    Ding, Yuchuan
    Zhao, Wenbo
    Ji, Xunming
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (02)
  • [43] Coronary no-reflow phenomenon
    Rezkalla S.H.
    Kloner R.A.
    Current Treatment Options in Cardiovascular Medicine, 2005, 7 (1) : 75 - 80
  • [44] THE NO-REFLOW PHENOMENON AND CPR
    GILSTON, A
    RESUSCITATION, 1993, 26 (02) : 211 - 212
  • [45] Management of the no-reflow phenomenon
    Butler, Michelle J.
    Chan, William
    Taylor, Andrew J.
    Dart, Anthony M.
    Duffy, Stephen J.
    PHARMACOLOGY & THERAPEUTICS, 2011, 132 (01) : 72 - 85
  • [46] No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion
    Reffelmann, T
    Hale, SL
    Dow, JS
    Kloner, RA
    CIRCULATION, 2003, 108 (23) : 2911 - 2917
  • [47] Anti-thrombin nanoparticles limit ischemia-reperfusion injury and no-reflow in myocardial infarction
    Pan, H.
    Lindon, A.
    Grabau, R.
    Dominguez, W.
    Wickline, S.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1871 - 1871
  • [48] Empagliflozin reduces both infarct size and no-reflow in a rat experimental myocardial ischemia/reperfusion model
    Dai, Wangde
    Carreno, Juan
    Pahlevan, Niema
    Alavi, Rashid
    Chavez, Jesus
    Kloner, Robert
    CIRCULATION, 2024, 150
  • [49] Study on Ginkgo diterpene lactones preventing no-reflow phenomenon after ischemia reperfusion by inhibiting pericyte contraction
    Wang, Zhiqiang
    Wang, Rongyu
    Yang, Dongdong
    CEREBROVASCULAR DISEASES, 2023, 52 : 35 - 35
  • [50] TIME COURSE OF THE NO REFLOW PHENOMENON DURING MYOCARDIAL REPERFUSION, DEPENDING ON DURATION OF PRECEDING ISCHEMIA
    KOGAN, AK
    MIEEGOMBYN, A
    LOSEV, NI
    KUDRIN, AN
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1986, 101 (01) : 19 - 22